Viewing Study NCT04053803


Ignite Creation Date: 2025-12-24 @ 7:39 PM
Ignite Modification Date: 2025-12-27 @ 1:18 AM
Study NCT ID: NCT04053803
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2022-03-04
First Post: 2019-07-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
Sponsor: Imara, Inc.
Organization:

Study Overview

Official Title: An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2022-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
Detailed Description: This is an open-label extension study of IMR-687 in adult patients with SCA who were previously participants in the Phase 2a study titled "A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)."

This open-label extension study with IMR-687 will evaluate the long-term safety and tolerability of IMR 687 in adult SCA patients. Exploratory long-term PD parameters will also be examined.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2018-003805-25 EUDRACT_NUMBER None View